Your browser doesn't support javascript.
loading
Hepatic patatin-like phospholipase domain-containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans.
Ericson, Elke; Bergenholm, Linnéa; Andréasson, Anne-Christine; Dix, Carly I; Knöchel, Jane; Hansson, Sara F; Lee, Richard; Schumi, Jennifer; Antonsson, Madeleine; Fjellström, Ola; Nasr, Patrik; Liljeblad, Mathias; Carlsson, Björn; Kechagias, Stergios; Lindén, Daniel; Ekstedt, Mattias.
Afiliación
  • Ericson E; Genome Engineering, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Bergenholm L; Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Andréasson AC; Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Dix CI; Discovery Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Knöchel J; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Hansson SF; Translational Science and Experimental Medicine, Research and Early Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Lee R; Antisense Drug Discovery, Ionis Pharmaceuticals, Carlsbad, California, USA.
  • Schumi J; Preclinical Pharmacology and Translational Medicine, Verve Therapeutics, Cambridge, Massachusetts, USA.
  • Antonsson M; Early Biometrics and Statistical Innovation, Data Science and Artificial Intelligence, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Fjellström O; Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Nasr P; Projects, Cardiovascular, Renal, and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Liljeblad M; Department of Gastroenterology and Hepatology, Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
  • Carlsson B; Translational Science and Experimental Medicine, Research and Early Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Kechagias S; Early Clinical Development, Research and Early Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Lindén D; Department of Gastroenterology and Hepatology, Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
  • Ekstedt M; Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Hepatol Commun ; 6(10): 2689-2701, 2022 10.
Article en En | MEDLINE | ID: mdl-35833455
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad del Hígado Graso no Alcohólico Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: Hepatol Commun Año: 2022 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad del Hígado Graso no Alcohólico Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: Hepatol Commun Año: 2022 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Estados Unidos